|
AU2521600A
|
|
Treatment for verotoxin-producing escherichia coli
|
|
AU6553899A
|
|
Prevention and treatment of sepsis
|
|
EP1085906A1
|
|
Anti il6 antibodies in the prevention and treatment of inflammatory bowel disease
|
|
US6214343B1
|
|
Prevention and treatment of necrotizing enterocolitis
|
|
CA2296765A1
|
|
Soluble recombinant botulinum toxin proteins
|
|
US6046165A
|
|
Compositions and methods for identifying and testing TGF-β pathway agonists and antagonists
|
|
US5998381A
|
|
Compounds that bind bacterial pili
|
|
ZA9508990B
|
|
Vaccine and antitoxin for treatment and prevention of C. difficile disease
|
|
AU3968395A
|
|
Vaccine and antitoxin for treatment and prevention of C. difficile disease
|
|
CA2416318A1
|
|
Soluble, recombinant botulinum toxin proteins
|
|
US5736139A
|
|
Treatment of Clostridium difficile induced disease
|
|
US5719267A
|
|
Clostridial toxin disease therapy
|
|
US5919665A
|
|
Vaccine for clostridium botulinum neurotoxin
|
|
US5599539A
|
|
Therapy for clostridial botulinum toxin
|
|
EP0679083A1
|
|
Prevention and treatment of sepsis.
|
|
US5545721A
|
|
Conjugates for the prevention and treatment of sepsis
|
|
US5601823A
|
|
Avian antitoxins to clostridium difficle toxin A
|
|
US5605691A
|
|
Immunologically active proteins from inclusion bodies
|
|
US5466672A
|
|
Therapeutic use of clostridium difficile toxin A
|
|
US5196193A
|
|
Antivenoms and methods for making antivenoms
|
